Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products
Iconovo AB (publ), that develops complete inhalation products for a global market, has entered into a strategic collaboration with Galenica AB – a company specializing in the development and manufacture of pharmaceuticals for clinical studies. The main purpose of the collaboration is to facilitate the manufacturing of clinical trial material for companies developing new drugs for Iconovo's innovative single dose inhaler ICOone.
Iconovo extends collaboration with ISR with an agreement worth 13.6 million Swedish kronor (SEK)
Iconovo AB expands its collaboration with immunotherapy company Immune System Regulation (ISR) that accelerates the development of an inhaled vaccine for covid-19. The contract value of the collaboration between ISR and Iconovo increases by 13.6 million SEK. Iconovo is also entitled to low, single-digit royalty on the sale of the finalized product.
Abbreviated year-end report 1 January – 31 December 2021
Significant progress in Iconovo’s three strategic business areas
Iconovo meddelar att en jämförande klinisk studie mellan ICOres budesonide/formoterol och Symbicort Turbuhaler har slutförts
Iconovo AB (publ), ett företag som utvecklar kompletta inhalationsprodukter för en global marknad, meddelar idag att en klinisk farmakokinetisk pilotstudie som jämför ICOres® budesonid/formoterol och Symbicort® Turbuhaler® har slutförts framgångsrikt. Studien, som genomfördes av Amneal Pharmaceuticals, har gett värdefull information som stöder fortsatt utveckling av ICOres budesonide/formoterol som en potentiell generisk ersättningsprodukt för Symbicort® Turbuhaler® vid behandling av astma och KOL.
Iconovo announces completion of comparative clinical study of ICOres budesonide/formoterol and Symbicort Turbuhaler
Iconovo AB (publ), a company developing complete inhalation products for a global market, today announces that a clinical pilot pharmacokinetic study, comparing the pharmacokinetic profile of ICOres budesonide/formoterol and Symbicort® Turbuhaler®, has been successfully concluded. The study, which was carried out by Amneal Pharmaceuticals, has provided valuable data that supports continued development of ICOres budesonide/formoterol as a potential generic substitution of Symbicort® Turbuhaler® for the management of asthma and COPD.
Iconovo establishes Iconovo Pharma AB as a subsidiary for pharmaceutical sales in the Nordic countries
Iconovo AB (publ), that develops complete inhalation products for a global market, has registered the subsidiary Iconovo Pharma AB with the Swedish Companies Registration Office. This is part of the previously communicated strategy to establish an infrastructure for in-house pharmaceutical sales in the Nordic market. Iconovo's goal is to reach sales revenues of SEK 200 million by 2026, of which approximately one third is estimated to come from Iconovo Pharma.
Iconovo etablerar dotterbolaget Iconovo Pharma AB för läkemedelsförsäljning i Norden
Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, har registrerat dotterbolaget Iconovo Pharma AB hos Bolagsverket. Detta är ett led i den tidigare kommunicerade strategin att etablera en infrastruktur för läkemedelsförsäljning i egen regi på den nordiska marknaden. Iconovos målsättning är att år 2026 nå försäljningsintäkter om 200 MSEK varav cirka en tredjedel beräknas komma från Iconovo Pharma.
First granted ICOone® patent in China
The Chinese Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone.
Första godkända patentet i Kina för ICOone®
Iconovo AB (publ) meddelar att den kinesiska patentmyndigheten har informerat att de avser att godkänna (Notice of Allowance) ett patent avseende Iconovos inhalatorplattform ICOone.
Abbreviated interim report 1 January – 30 September 2021
New nasal inhaler has great potential in treatment of COVID-19
